Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform
(2015)
Journal Article
Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise biomedicine. Global burden of heart failure will soon reach USD $90bn, while unexpected cardiotoxicity underlies 28% of drug withdrawals. Advances in hPSC isolation, Cas... Read More about Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform.